In addition, Xu et al presented a unique case of a patient with cervical small cell carcinoma who developed hyperprogression after treatment with pembrolizumab and showed a correlation between the AKT1 E17K mutation and HPD.56 The gene discussed is AKT1; the disease is cervical small cell carcinoma.